The U.K.-based drugmaker’s Fasenra is now the third respiratory biologic with the option to be self-administered, improving access for patients with severe eosinophilic asthma. It comes as a prefilled, single-use autoinjector.
The treatment, which was originally approved in the U.S. in 2017, is to be used every eight weeks by patients 12 years and older. Self-administration was already approved in the European Union.
Read the full news release here.
More articles on pharmacy:
Telemedicine startup to open first brick-and-mortar pharmacy
Top 10 pharmacy stories in September
Novant Health to open health clinics inside Walgreens
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
